As LPL-mediated lipolysis of lipoproteins is suggested to be a key source of FAs for cardiac use [2], its regulation and its modification following diabetes require thorough investigation to help us understand the pathophysiology of diabetic heart disease as it relates to the metabolism of FAs, in order to advance its clinical management. The gene discussed is LPL; the disease is diabetes mellitus.